Sterling Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Sterling Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.6K	Sell	541 -427	-44%	-$6.54K	﹤0.01%	2142
2026 Q1	$13.4K	Sell	968 -9	-0.9%	-$143	﹤0.01%	2218
2025 Q4	$15.9K	Buy	977 +615	+170%	+$10K	﹤0.01%	2357
2025 Q3	$5.42K	Buy	362 +1	+0.3%	+$12	﹤0.01%	2749
2025 Q2	$4.21K	Sell	361 -1,637	-82%	-$14.9K	﹤0.01%	2605
2025 Q1	$14.8K	Sell	1,998 -1,712	-46%	-$13.2K	﹤0.01%	1747
2024 Q4	$22.2K	Buy	3,710 +3,307	+821%	+$18.2K	﹤0.01%	1842
2024 Q3	$2.06K	Buy	+403	New	+$1.76K	﹤0.01%	2169

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Sterling Capital Management's ADPT Position: Q2 2026 in Review

Sterling Capital Management reduced its Adaptive Biotechnologies (ADPT) stake by 44% in Q2 2026, selling an estimated $6.54K and leaving 541 shares worth $11.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2142.

Sterling Capital Management first reported a position in ADPT in Q3 2024 and has held it in 8 quarters since. The position peaked at $22.2K in Q4 2024. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

Sterling Capital Management held 541 shares of Adaptive Biotechnologies worth $11.6K as of Q2 2026.
Sterling Capital Management sold 427 Adaptive Biotechnologies shares in Q2 2026, an estimated $6.54K.
Adaptive Biotechnologies made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2142 holding.
Sterling Capital Management first reported a position in Adaptive Biotechnologies in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's Adaptive Biotechnologies position peaked at $22.2K in Q4 2024.
300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.